Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 4/2016

01-04-2016 | Original Article

Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis

Authors: Niveditha Muralidharan, Christina Mary Mariaselvam, Mithun CB, Vir Singh Negi

Published in: Clinical Rheumatology | Issue 4/2016

Login to get access

Abstract

Methotrexate (MTX) is the most commonly used disease-modifying drug to treat rheumatoid arthritis (RA). Although there are no reliable molecular markers to predict the treatment response and adverse effects to MTX therapy, the polymorphisms in genes coding for MTX metabolizing enzymes and transporters may play a crucial role. The reduced folate carrier-1 (RFC-1) is a bidirectional anion exchanger which transports MTX and folinic acid. It is reported to influence MTX treatment response and adverse effects in some ethnic populations but not in others. It is also associated with susceptibility to various diseases including systemic lupus erythematosus (SLE). The present study was aimed at investigating the role of RFC-1 80G > A gene polymorphism in association with disease susceptibility, MTX treatment response and the MTX-induced adverse events in the South Indian Tamil patients with rheumatoid arthritis. The RFC-1 80G > A gene polymorphism was investigated in 327 patients with RA and in 322 healthy controls by PCR-RFLP method. It was found that the heterozygous RFC-1 80 GA genotype was associated with protection against RA [p = 0.02, odds ratio (OR) 0.69, 95 % confidence interval (CI) 0.50–0.95]. However, it was not found to be associated with MTX treatment response. The RFC-1 G allele frequency was higher in patients with adverse effects, but the difference was not statistically significant (p = 0.08, OR 1.44, 95 % CI 0.97–2.13). RFC-1 80G > A gene polymorphism confers protection for RA. However, it is not associated with MTX treatment response and MTX-induced adverse effects in South Indian Tamil patients with RA.
Literature
1.
Colmegna I, Ohata BR, Menard HA (2012) Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther 91:607–620CrossRefPubMed
2.
Dalrymple JM, Stamp LK, O’Donnell JL, Chapman PT, Zhang M, Barclay ML (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299–3308CrossRefPubMed
3.
Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, Barton A (2013) MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 13:137–147CrossRefPubMed
4.
Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW (2006) Genetic markers of treatment response in rheumatoid arthritis. Curr Rheumatol Rep 8:369–377CrossRefPubMed
5.
Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366–1377CrossRefPubMed
6.
Burgos PI, Danila MI, Kelley JM, Hughes LB, Bridges SL Jr (2009) Understanding personalized medicine in rheumatoid arthritis: a clinician’s guide to the future. Ther Adv Musculoskelet Dis 1:97–105CrossRefPubMedPubMedCentral
7.
Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, Assaraf YG, Dijkmans BA (2004) Sulphasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 50:2130–2139CrossRefPubMed
8.
Ifergan I, Jansen G, Assaraf YG (2008) The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation RFC as a double edged sword in folate homeostasis. J Biol Chem 283:20687–20695CrossRefPubMedPubMedCentral
9.
Bi XH, Zhao HL, Zhang ZX, Zhang JW (2009) Association of RFC1 A80G and MTHFR C677T polymorphisms with Alzheimer’s disease. Neurobiology Aging 30:1601–1607CrossRef
10.
Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP (2000) A polymorphism (80 G > A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70:310–315CrossRefPubMed
11.
12.
Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA (2007) Transcription regulatory polymorphism -43 T > C in the 5’ flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol Int 27:1057–1061CrossRefPubMed
13.
Rupasree Y, Naushad SM, Rajasekhar L, Kutala VK (2014) Epigenetic modulation of RFC1, MHC2TA, and HLA-DR in systemic lupus erythematosus: Association with serological markers and six functional polymorphisms of one-carbon metabolic pathway. Gene 536:45–52CrossRefPubMed
14.
Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573–586CrossRefPubMedPubMedCentral
15.
van Gestel AM, Prevoo ML, van 't Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40CrossRefPubMed
16.
17.
Gellekink H, Blom HJ, den Heijer M (2007) Associations of common polymorphisms in thymidylate synthase, reduced folate carrier and 5-aminoimidazole-4-carbocamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase genes eith folate and homocysteine levels and venous thrombosis risk. Clin Chem Lab Med 45:471–476CrossRefPubMed
18.
Swierkot J, Szechiński J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473–492PubMed
19.
Cronstein BN (2005) Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172CrossRefPubMed
20.
Sadlish H, Murray RC, Williams FM, Flintoff WF (2000) Mutations in the reduced-folate carrier affect protein localization and stability. Biochem J 346:509–518CrossRefPubMedPubMedCentral
21.
Yates Z, Lucock M (2005) G80A reduced folate carrier SNP modulates cellular uptake of folate and affords protection against thrombosis via a non homocysteine related mechanism. Life Sci 77:2735–2742CrossRefPubMed
22.
Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH (2001) Single nucleotide polymorphisms in the human reduced folate carrier Characterization of a High-Frequency G/A Variant at Position 80 and Transport Properties of the His27 and Arg27 Carriers. Clin Cancer Res 7:3416–3422PubMed
23.
De Marco P, Calevo MG, Moroni A, Merello E, Raso A, Finnell RH, Zhu H, Andreussi L, Cama A, Capra V (2003) Reduced folate carrier polymorphism (80A—G) and neural tube defects. Eur J Hum Genet 11:245–252CrossRefPubMed
24.
Grabar PB, Logar D, Lestan B, Dolzan V (2008) Genetic determinants of methotrexate toxicity in Rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 64:1057–1068CrossRef
25.
Ghodke Y, Chopra A, Shintre P, Puranik A, Joshi K, Patwardhan B (2011) Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian J Med Res 133:274–279PubMedPubMedCentral
26.
Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, Grover R, Arya V, Dhir V, Gupta R, Kumar U, Juyal RC (2008) B K T Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 18:1041–1049CrossRefPubMed
27.
Burzynski M, Duriagin S, Mostowska M, Wudarski M, Chwalinska-Sadowska H, Jagodzinski PP (2007) MTR 2756 A > G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population. Lupus 16:450–454CrossRefPubMed
28.
Shao S, Li X-R, Cen H, Yin Z-S (2014) Association of AIRE polymorphisms with genetic susceptibility to rheumatoid arthritis in a Chinese population. Inflammation 37:495–499CrossRefPubMed
29.
Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y et al (2011) The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet 20:2680–2685CrossRefPubMed
30.
Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095CrossRefPubMed
31.
Kung TN, Dennis J, Ma Y, Xie G, Bykerk V, Pope J, Thorne C, Keystone E, Siminovitch KA, Gagnon F (2014) RFC1 80G > A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. Arthritis Rheumatol 66:1111–1120CrossRefPubMed
32.
Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M (2007) Reduced folate carrier-1 80G > A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 7:404–407CrossRefPubMed
33.
Hayashi H, Tazoe Y, Tsuboi S, Horino M, Morishita M, Arai T, Ohshima M, Matsuyama T, Kosuge K, Yamada H, Tsuji D, Inoue K, Itoh K (2013) A single nucleotide polymorphism of reduced folate carrier 1 (RFC1) predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab Pharmacokinet 28:164–168CrossRefPubMed
34.
Samara SA, Irshaid YM, Mustafa KN (2014) Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther 52:746–755CrossRefPubMed
35.
Lima A, Bernardes M, Sousa H, Azevedo R, Costa L, Ventura F, Seabra V, Medeiros R (2014) SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics 15:807–820CrossRefPubMed
36.
Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, Smith K, Caldwell J, Furst DE (2004) Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14:733–739CrossRefPubMed
37.
Ando Y, Shimada H, Matsumoto N, Hirota T, Oribe M, Otsuka E, Ishii K, Morimoto T, Ohashi K, Ieiri I (2013) Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacokinet 28:442–445CrossRefPubMed
38.
Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T (1999) Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 42:1609–1616CrossRefPubMed
Metadata
Title
Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis
Authors
Niveditha Muralidharan
Christina Mary Mariaselvam
Mithun CB
Vir Singh Negi
Publication date
01-04-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2917-y

Other articles of this Issue 4/2016

Clinical Rheumatology 4/2016 Go to the issue

Original Article

Transitional care in clinical networks for young people with juvenile idiopathic arthritis: current situation and challenges

Review Article

Rheumatologic manifestations of primary immunodeficiency diseases

Review Article

Acute sacroiliitis

Original Article

Autoantigen-targeting microRNAs in Sjögren’s syndrome

Case Based Review

Focal myositis presenting as pseudothrombophlebitis of the arm

Brief Report

The role of outcome expectancies for a training program consisting of meditation, breathing exercises, and cold exposure on the response to endotoxin administration: a proof-of-principle study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits